LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Japan ,United States ,United Kingdom ,Belgium ,Kenilworth ,Warwickshire ,Cambridge ,Cambridgeshire ,Canada ,Brussels ,Bruxelles Capitale ,London ,City Of ,Scotland ,American ,Jessica Mcduell ,Daiichi Sankyo ,Andrew Tutt ,Brendan Mcevoy ,Roy Baynes ,Susan Galbraith ,King College London ,National Surgical Adjuvant Breast ,Union For International Cancer ,European Society For Medical Oncology Virtual Plenary ,Frontier Science Technology Research Foundation ,Nasdaq ,Company On Twitter Astrazeneca ,American Society Of Clinical Oncology Annual Meeting ,Breast International Group ,Merck Co Inc ,Astrazeneca ,Head Of Global Clinical Development ,American Cancer Society ,Development Agreement ,Merck Research Laboratories ,National Institutes Of Health ,Drug Administration ,Gynecologic Oncology Group ,Us National Cancer Institute ,Oncology Group ,Institute Of Cancer Research ,International Breast Cancer Study Group Trials ,Radiation Therapy Oncology Group ,Olympia Phase ,European Society ,Medical Oncology Virtual ,Frontier Science ,Technology Research Foundation ,Clinical Oncology Annual Meeting ,New England Journal ,Global Chair ,Cancer Research ,College London ,Executive Vice President ,Senior Vice President ,Global Clinical Development ,Chief Medical Officer ,Acute Myeloid Leukemia ,Fetal Toxicity ,Thromboembolic Events ,First Line Maintenance ,Advanced Ovarian ,First Line Maintenance Advanced Ovarian Cancer ,Maintenance Recurrent Ovarian ,Ovarian Cancer After ,More Lines ,Adjuvant Treatment ,High Risk Early Breast ,Negative Metastatic Breast ,Metastatic Pancreatic ,Metastatic Castration Resistant Prostate ,Positive Advanced Ovarian Cancer ,Line Maintenance ,Prescribing Information ,Cancer Institute ,National Institutes ,Bowel Project ,Southwest Oncology ,Cooperative Research ,Rare Diseases ,High Risk ,Primary Breast Cancer ,Accessed February ,Mutated Breast ,Cancer Statistics ,Mortality Worldwide ,Cancer Journal ,Breast Cancer Facts ,International Cancer ,Cancer Medicines ,Hazard Rates ,Breast Cancer During ,Results From ,Cellular Heterogeneity ,Breast Cancer ,Genome Stability ,Cancer Stemness ,Business Wire ,Technology ,Science ,Health ,Business ,Cancer ,Chemotherapy ,